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Summary
Immune checkpoint inhibitors have revolutionized cancer 
treatment with patient improved survival, quality of life, and 
a longer response. However, up to 30% of patients experi-
ence paradoxical accelerated tumor progression early after 
immune-checkpoint blockade therapy. This phenomenon is 
also known as hyperprogression (HP). Unlike other responses, 
such as pseudoprogression or natural progression, HP causes 
worse survival outcomes in patients. Older age, higher meta-
static burden, and previous radiation have been indepen-
dently associated with HP. Even though the exact molecular 
mechanism underlying HP after immune-checkpoint block-
ade therapy remains unknown, oncogenic signaling activa-
tion including MDM2 amplification or EGFR alterations, the 
modification of tumor microenvironment by radiotherapy 
with immune checkpoint inhibitors, and alterations in im-
mune landscape of tumors have been hypothesized as the 
biological mechanisms behind HP. Patients with HP have 
been presented with poor prognosis and increased deleteri-
ous mutations in cancer genes, along with alterations in the 
tumor microenvironment. As immune checkpoint inhibitors 
have been more widely accepted by oncologists, proper as-
sessment of this unique tumor response remains challenging 
in clinical practice. This work documents the recent findings 
on epidemiology, biological and clinicopathological factors 
of HP after immunotherapy. 
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Introduction
 Evasion of immune system has been identi-
fied as a hallmark of cancer [1]. Cancer cells ac-
complish “immunoediting” by exploiting several 
immunity-related processes including regulatory 
T cell function and antigen presentation [2]. Elu-
cidating the molecular interplay between cancer 
cells and the immune system has contributed to 
the development of immune checkpoint inhibitors 
(ICIs). Clinical engagement of immune checkpoint 
inhibitors targeting programmed cell death protein 
1 (PD-1), programmed cell death ligand 1 (PD-L1), 
and cytotoxic T lymphocyte-associated protein 4 
(CTLA-4) has revolutionized cancer therapy [3]. 
ICIs have become a standard treatment for mul-
tiple malignancies including non-small cell lung 
cancer (NSCLC) [4], renal cell carcinoma (RCC) [5], 
urothelial carcinoma [6], Hodgkin’s lymphoma [7], 
head and neck squamous cell carcinoma (HNSCC) 
[8], melanoma [9], and Merkel cell carcinoma [10]. 
Overall, response rates for immune checkpoint 
blockade as monotherapy in solid tumors range 
from 20 to 40% [11-13]. Despite the unprecedented 
improvements in overall survival rates , some pa-
tients present with unconventional responses such 
as pseudoprogression, mixed response, and hyper-
progression (HP) [14]. Distinct response patterns 
elicited by ICIs have raised clinical concern that 
immunotherapy may be harmful to some patients. 
Among these patterns, accumulated evidence from 
retrospective data and case studies indicated that 
This work by JBUON is licensed under a Creative Commons Attribution 4.0 International License.
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immune checkpoint blockade may accelerate tu-
mor growth in a remarkable subset of patients, 
with rates ranging from 4 to 29% through mul-
tiple malignancies [15-19]. This phenomenon is 
also known as HP. In contrast to pseudoprogres-
sion which is defined as an initial tumor fluctua-
tion followed by tumor shrinkage [20], patients 
with hyperprogressive disease (HPD) display poor 
prognosis and survival outcomes. The incidence, 
molecular basis, and predictive biomarkers of HP 
have not been fully understood. In this review, we 
aim to provide recent clinical studies on HP as well 
as discussing the underlying biological and clin-
icopathological mechanisms, potential predictors 
or biomarkers related to this phenomenon. 
Hyperprogression: occurrence and clini-
cal significance 
 HP is a phenomenon characterized by a rapid 
increase in tumor growth rate after immunothera-
py. It was first described by Champiat et al [15] in 
patients receiving PD-1/PD-L1 inhibitors in phase 
1 clinical trial. Moreover, subsequent case studies 
reported “disease flare” after the initiation of im-
mune checkpoint inhibitors (ICPs) in patients with 
NSCLC [21,22], squamous cell NSCLC [23], meta-
static clear cell renal cell carcinoma (RCC) [24,25], 
melanoma [26], lymphoma [27] and sarcoma [28]. 
In addition to the above-mentioned case studies, 
a number of retrospective studies investigated 
Authors Study
design
Tumour 
type
Treatment Number of
evaluated 
patients
Number of 
Hyperprogressors
Rate 
(%)
Definition of
Hyperprogression
Champiat et al. 
(2017)
Retrospective Multiple 
tumour 
types1
PD-1/PD-L1 
inhibitors
131 12 9.2 •	RECIST progression at first 
evaluation
•	TGR ratio>2 (compared to 
preimmunotherapy period)
Saâda-Bouzid 
et al. (2017)
Retrospective HNSCC PD-1/PD-L1 
inhibitors
34 10 29.4 •	TGK ratio>2 (compared to 
preimmunotherapy period )
Kato et al. 
(2017)
Genomic 
Analysis
Multiple 
tumour 
types2
CTLA-4, 
PD-1/PD-L1 
inhibitors
155 6 3.9 •	TTF<2, 50>increase in 
tumour burden compared 
with preimmunotherapy,
•	>2 fold increase in 
progression pace
Ferrara et al. 
(2017)
Retrospective NSCLC PD-1/PD-L1 
inhibitors
406 56 14 •	RECIST progression at first 
evaluation,
•	ΔTGR increase>1.5 
compared with 
preimmunotherapy
Weiss et al. 
(2017)
Prospective Multiple 
tumour 
types3
CTLA-4, 
PD-1/PD-L1 
inhibitors
56 6 11 -
Kanazu et al. 
(2018)
Retrospective NSCLC Nivolumab 87 5 5.75 •	Multiple predictive 
biomarkers
Kim et al. 
(2018)
Retrospective NSCLC PD-1/PD-L1 
inhibitors
220 37 17 •	TGK ratio2 (compared to 
preimmunotherapy period )
Lo Russo et al. 
(2018)
Prospective NSCLC PD-1/PD-L1 
inhibitors
152 39 25.7 •	Combination of Clinical and 
radiological criteria4
HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small cell lung cancer; TTF: time-to-treatment failure; TGR: tumour growth 
rate; TGK: tumour growth kinetics; TGKR: ratio of post-treatment TGK to pre-treatment TGK
1Melanoma, renal carcinoma, colorectal cancer, urothelial cancer, hepatocellular carcinoma, head and neck carcinoma, cutaneous squamous 
cell carcinoma, breast cancer, ovarian cancer, glioblastoma endometrium cancer, glioblastoma, cervix cancer, gastric and oesophagus can-
cer, mesothelioma, pancreas cancer, sarcoma
2Melanoma, non-small cell lung cancer, squamous cell carcinoma of head and neck, cutaneous squamous cell carcinoma, renal cell carci-
noma, and colorectal cancer.
3Breast cancer, colon cancer, lung cancer, pancreatic cancer, renal cancer, melanoma.
4Combination of clinicoradiological criteria.
Table 1. The incidence of hyperprogression after immune-checkpoint blockade therapy
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the incidence of HP in cohorts of patients treated 
with ICIs (Table 1). Champiat et al [15] retrospec-
tively analyzed the prevalence of HP among 131 
patients treated with PD-1 and PD-L1 inhibitors. 
Nine % (n=12 of 131) of patients with multiple 
tumor types experienced HP, which was defined 
as RECIST progression at first evaluation and >2-
fold increase in tumor growth rate (TGR) early af-
ter ICI treatment. In another study investigating 
the occurrence of HP in 155 patients treated with 
immunotherapy, 6 advanced cancer patients were 
presented with HP, defined as time to treatment 
failure (TTF) less than 2 months, >50% growth in 
tumor burden compared with pre-immunotherapy 
period, and >2-fold increase in progression speed 
[16]. Moreover, Saâda-Bouzid et al [17] reported 
the highest incidence of hyperprogressive disease 
(HPD) to be up to 29% (n=10 of 34) in a retrospec-
tive analysis of 34 patients with HNSCC. Closer to 
findings of Champiat et al [15] in NSCLC patients, 
around 14% (n=56 of 406) of patients with NSCLC 
were found to have HP in the multicenter retro-
spective study [18]. Of note, in the study of tumor 
cell-free DNA copy number for cancer diagnostics, 
Weiss et al [29] found that 9% (n=11 of 56) of pa-
tients with multiple tumor types experienced HP 
after initiation of immunotherapy. More recently, 
17% (n=37 of 220) of NSCLC patients receiving 
immune-blockade therapy were found as hyperpro-
gressors, whose tumor growth kinetics (TGK) ratio 
was greater than 2 compared to that in pre-immu-
notherapy period [19]. Finally, Lo Russo et al [30] 
reported 25.7% (n=39 of 152) of NSCLC patients 
treated with ICIs as hyperprogressors. These find-
ings are consistent with results from several phase 
3 clinical trials comparing immune checkpoint in-
hibitors with cytotoxic chemotherapy in patients 
with NSCLC (Checkmate 057), advanced urothelial 
carcinoma (Keynote 045 and IMvigor211), HNSCC 
(Checkmate 141), advanced NSCLC (Checkmate 
026), and NSCLC with high tumor mutational bur-
den (Checkmate 227). In these clinical trials, overall 
survival (OS) and progression-free survival (PFS) 
declined in the first 3 months after the initiation of 
ICIs [12,31-34], indicating that a subset of patients 
receiving immunotherapy experienced unexpected 
disease progression or death. To illustrate better, 
the mortality was higher in patients with urothe-
lial carcinoma receiving nivolumab (20%) than in 
those receiving docetaxel during the first 3 months 
of treatment in the Checkmate 057 clinical trial 
[12]. Clinical trials displaying this kinetics can be 
regarded as remarkable examples of HP. It is signif-
icant to emphasize that patients in trials mentioned 
above had previously received systemic therapies. 
However, evaluation of HP was not possible due to 
the lack of pre-imaging data. 
 Although there hasn’t been a universally ac-
cepted description of HP, parameters have been 
proposed by a handful of studies published so far 
[15-19]. The definition of HP may be depicted as 
RECIST progression at the first evaluation, TTF less 
than 2 months, increase in tumor size greater than 
50% compared to pre-immunotherapy phase, and 
increase in progression speed ≥ to 2-fold. There 
have been various parameters for assessing HPD, 
such as TGR and TTF. TGR incorporates the RE-
CIST, with the sum of target lesions and the time 
between the tumor evaluations, enabling more dy-
namic evaluation of tumor kinetics [15]. Another 
Figure 1. Biological and clinicopathological factors for hyperprogression.
Hyperprogression after immunotherapy: A comprehensive review 2235
JBUON 2019; 24(6): 2235
approach, TGK is based on the variations of the 
sum of largest tumor growth but does not take into 
account the 3D tumor growth. This can overesti-
mate the rate of HP in patients [17]. Heterogeneity 
in methodology may contribute to the significant 
differences in the prevalence of HP among studies. 
More definitive parameters about pretreatment tu-
mor kinetics are needed for assessing HP.
Biological and clinicopathological fac-
tors of hyperprogression 
 In the above-mentioned studies, immune 
checkpoint inhibitors may induce an accelerated 
tumor growth in some patients. It is essential to 
elucidate the mechanisms of HP, with biological 
and clinical factors. This may help select patients 
who might benefit from immune checkpoint inhibi-
tors. Several studies have proposed factors associ-
ated with HPD based on retrospective data and case 
studies (Figure 1). 
 Older age: One study found that older age 
(>65 years) was associated with higher incidence 
of HPD, with worse survival outcomes [15]. This 
situation can be explained by the differences in 
the immune system of older patients, such as an 
increase in the level of inflammatory cytokines 
or altered protein expression in T cell inhibitory/
stimulatory pathways [35,36]. In accordance with 
the changing immune system in older patients, in-
dependent phase 3 clinical trials on ICIs indicated 
that older patients had less benefit than younger 
patients [37,38]. Moreover, age-related immunity 
dysfunction (ARID) causes a decrease in numbers, 
diversity, and functions of T cells, hence adversely 
affecting T cell immunity against tumors [39,40]. 
Up to now, there is limited research on this issue 
and further prospective studies are highly cru-
cial to elucidate the mechanism of age-related
HPD.
 High-metastatic burden: HPD was found to be 
more common in patients with advanced NSCLC 
having high-metastatic burden compared to those 
without high-metastatic burden (62.5% ; 35 of 56 
vs 42.6% i.e. 149 of 350 ; p=0.006) [18]. The exact 
mechanism linking the high metastatic burden to 
HPD is unknown. Additional studies are needed to 
address this issue. 
 MDM2 gene amplification: Mouse double 
minute 2 homolog (MDM2) amplification has been 
detected in 7% of human cancers [41]. The main 
role of MDM2 is to inhibit p53 tumor suppres-
sor gene by stimulating its degradation [42]. Even 
though there has been limited research on the ge-
netic basis of HPD, comprehensive genomic pro-
filing of patients with HPD indicated that MDM2/
MDM4 amplification correlates with the acceler-
ated tumor growth and poor prognosis [16]. In a 
research by Singavi et al [43], somatic alterations 
were analyzed in 4 patients with HPD by using 
next generation sequencing (NGS). MDM2/4 gene 
amplification has been detected in 66% of patients 
with HPD. The role of copy number alterations in 
MDM2 gene as a putative predictive biomarker for 
HP merits further investigation in large cohorts of 
patients.
 Locoregional recurrence in the irradiated area: 
A number of studies have reported that previous 
radiation may predispose to HP. Saâda-Bouzid et 
al [17] found that HP occurred in 50% (n=9 of 18) 
of head and neck cancer patients with a regional 
recurrence during immune-blockade therapy. It is 
important to emphasize that almost all patients 
in this study had previous radiotherapy. In a case 
study reported by Ogata et al [44], a patient with 
gastric cancer who received a single dose nivolum-
ab following radiotherapy experienced HPD within 
the irradiated field. In head and neck cancer as well 
as in gastric cancer, locoregional recurrence in an 
irradiated field may play a role in the incidence 
of HPD. Radiotherapy induces the production of 
neoantigens in the tumor, which may cause rapid 
progression in the irradiated field [45]. So far, the 
exact mechanism linking HP to locoregional recur-
rence in the irradiated area remains unknown and 
further prospective controlled studies are needed. 
 EGFR alterations: Immune checkpoint inhibi-
tors have had limited effectiveness in NSCLC pa-
tients with anaplastic lymphoma kinase (ALK) re-
arrangement or epidermal growth factor receptor 
(EGFR) mutations. In a phase 3 randomized clini-
cal trials comparing immune checkpoint inhibitors 
to chemotherapy as a second or subsequent line 
of therapy in a small number of NSCLC patients 
with ALK/EGFR alterations, subgroup analyses 
indicated that patients with ALK/EGFR-positive 
disease did not benefit from immune-blockade 
therapy [46,47]. In addition, Gainor et al [48] retro-
spectively evaluated objective responses among 58 
NSCLC patients with ALK rearrangements or EGFR 
mutations to determine the activity of ICIs within 
molecular subgroups. They found that objective re-
sponses were seen in only 3.6% (n=1 of 28) of ALK- 
or EGFR-positive patients versus 23.3% of (n=7 of 
30) those with ALK-negative/unknown and EGFR 
wild-type patients. According to preclinical data, 
lower expressions of PD-L1 and decreased levels 
of CD8+ tumor-infiltrating lymphocytes (TILs) have 
been found in patients EGFR/ALK-positive patients 
compared to those with EGFR/ALK-negative, ad-
dressing the limited activity of ICIs in these clini-
cally relevant molecular subgroups [48].
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 Besides MDM2/MDM4 amplification, EGFR 
alterations have been shown to be independently 
associated with HP. In a case study presented by 
Chubachi et al [21], the patient had received mul-
tiple lines of chemotherapies and tyrosine kinase 
inhibitors (TKI) prior to nivolumab administra-
tion. The disease was indolent during EGFR-TKIs 
treatment but progressed dramatically following 
nivolumab therapy. The authors suggested that the 
disease flare occurred after the discontinuation of 
EGFR-TKIs and may be a putative predictive fac-
tor for acceleration in disease progression during 
nivolumab treatment. In the cohort of patients ana-
lyzed by Kato et al [16], 20% (n=2 of 10) of patients 
with EGFR alterations demonstrated HP, with 41.7 
fold increase in progression speed. Another ab-
stract presented by Singavi et al [43], 50% (n=1 of 
2) of patients with EGFR alterations showed HP. 
The molecular link between EGFR alterations and 
HP remains unclear. Further research is needed to 
address this issue. 
 Tumor mutational burden: Tumor mutational 
burden (TMB) has been correlated with greater effi-
cacy of immunotherapies independent of PD-L1 ex-
pression [49]. However, the possible utility of TMB 
in patients with HPD is still unknown. Singavi et al 
[43] found that patients with HPD have TMB, with 
score ranging from 4-13 / Mb that is grouped as a 
low intermediate. More recently, Weiss et al [29] 
described that chromosomal instability quantifi-
cation by next-generation sequencing (NGS) from 
plasma/serum derived cell-free DNA (cfDNA) could 
be used for predicting hyperprogressive response 
to immunotherapy. More research is needed to elu-
cidate the relationship between TMB and HPD. 
 In addition to factors mentioned above, no re-
markable differences in the prevalence of HP were 
reported among patients receiving anti-PD-1 or 
anti-PD-L1 inhibitors [15,17,18]. Interestingly, no 
association has been found between HP and CTLA-
4 inhibitor monotherapy. Furthermore, there was 
no association between HP and disease stage or 
performance status at baseline [15,17,18]. Mostly, 
HP is confused with “flare-up” phenomenon relat-
ed to the discontinuation of previously targeted 
therapies. However, several studies reported that 
the types and number of previous therapies had 
no effect in the prevalence of HP [15,17,18]. There 
were no significant differences between patients 
with or without HP in terms of blood character-
istics at the baseline (lymphocyte counts, serum 
levels of albumin or fibrinogen) [15,17]. According 
to retrospective data, HP was observed in multiple 
tumor types including NSCLC, HNSCC, melanoma, 
urothelial cancer, colorectal cancer, ovarian cancer, 
biliary tract carcinomas and lymphomas, suggest-
ing that HP was independent of tumor histology 
[15,17]. Finally, no association was found between 
HP and PD-L1 expression in tumors, tumor bur-
den at baseline, and the number of metastatic sites 
[15,17]. Interestingly, it has been described that pa-
tients with HPD have lower rates of new lesions 
[15].
 
Hypotheses about mechanisms behind 
Hyperprogression 
 The exact molecular mechanism underlying 
HP after immune-checkpoint blockade therapy re-
mains unknown. So far, oncogenic signaling ac-
tivation including MDM2 amplification or EGFR 
alterations, the modification of tumor microenvi-
ronment by radiotherapy with immune checkpoint 
inhibitors, and alterations in the immune landscape 
of tumors have been hypothesized as biological 
mechanisms behind HP (Figure 2). 
 MDM2 amplification was detected in patients 
with HPD after immune-checkpoint blockade ther-
apy [16,43]. A possible explanation for the role of 
MDM2 in HP is related to the inactivation of p53, 
which is one of the key drivers of carcinogenesis. 
MDM2 plays a crucial role in the regulation of p53, 
Figure 2. Potentially underlying mechanisms for hyperprogression.
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known as the guardian of the genome [50]. MDM2, 
an ubiquitin protein ligase, directly inhibits N-ter-
minal transactivation domain of p53 and triggers 
its degradation by the proteasome [51]. Immune 
checkpoint inhibitors may result in elevated inter-
feron (IFN)-γ which, in turn, activates JAK-STAT 
signaling pathway [52]. This leads to an increase in 
the expression of interferon regulatory factor (IRF)-
8 [53]. Binding of IRF-8 to the MDM2 promoter in-
duces MDM2 expression [42,54]. This cascade may 
cause hyperexpression of MDM2 in the presence of 
MDM2 amplification. On the other hand, the loca-
tion of a gene on MDM2 amplicon may co-amplify 
with MDM2 [16]. Combination of MDM2 inhibitors 
with ICIs might be an effective strategy to avoid 
the risk of HPD in the future. Further investigation 
is crucial to clarify this hypothesis. 
 Beyond MDM2-mediated oncogenic signaling 
activation, it has been widely known that PD-1/
PD-L1 axis exerts intrinsic functions in tumor cells 
[55]. Intrinsic PD-1 expression in tumor cells has 
been associated with rapid tumor progression after 
ICI treatment in preclinical models [55,56]. Consist-
ently, Du et al [56] suggested that PD1 blockade 
may lead to increase in tumor growth by interfering 
PD-1- mediated upregulation of proapoptotic pro-
teins such as BIM, G1 phase inhibitor (p15INK4), 
and cyclin-dependent kinase 2. More importantly, 
Kleffel et al [55] found that PD-1 inhibition sup-
pressed the growth in PD-1-expressing melanoma 
cells. Lorenz hypothesized that the differential ef-
fects of PD-1 signaling may vary depending on dif-
ferences in Src homology (SH) domain-containing 
protein tyrosine phosphatase (SHP) signaling in T 
cells and melanoma. SHP1 and SHP2 phosphatases 
are cellular mediators of PD-1 signaling, causing T 
cell anergy [57]. SHP2 is largely demonstrated as a 
proto-oncogene, whereas SHP1 suppresses tumor 
growth by degrading JAK kinases and dephospho-
rylating STAT3 [58,59]. Therefore, SHP differential 
partnering may take part in the molecular interplay 
of HP. 
 The modification of tumor microenvironment 
by previous radiotherapy with ICIs might be anoth-
er potential mechanism leading to HP. As described 
previously, Saâda-Bouzid et al [17] found that al-
most all patients with HP had at least a locore-
gional recurrence in an irradiated field. Thus, the 
previous radiotherapy could contribute to the HPP 
supportingly, irradiation can decrease the effect of 
immunotherapy by upregulating PD-L1 expres-
sion and depleting tumor infiltrating leucocytes 
(TILs) [23,24]. Radiotherapy could adversely alter 
the antitumor immunity, with changes in tumor 
microenvironment after ICI treatment, leading to 
HP [60].
 Hyperactivation of PD-1/PD-L1 upstream may 
also lead to HP after immune-checkpoint blockade 
therapy. Immune activation is known to induce lo-
cal inflammation, matrix/tissue remodeling, angio-
genesis, and anaerobic metabolism, which facilitate 
tumor progression and spread to the distant parts 
of the body [61,62]. Reduced activity of PD-1 may 
induce the levels of oncogenic proteins such as 
nuclear factor of activated T cells 1 (NFATC1) and 
pro-oncogenic inflammatory transducers [63,64]. 
Moreover, downregulated PD-L1 may contribute to 
activation of proliferation pathways such as RAS 
MAPK and PI3K/Akt in the presence of enhancing 
genetic alterations [64].
 Alterations of the immune system cells could 
also mediate the HPD in patients. T cell responses 
have been at the center of antitumor immunity 
since immunotherapy in cancer attempts the acti-
vation and the expansion of specific cancer T cells 
[65]. Zuazo-Ibarra et al [66] underlined the role of 
CD4 THD cells in identifying the primary resist-
ance to therapy and the risk of HP after immune-
checkpoint blockade therapy. They found that low 
baseline circulating highly-differentiated CD28- 
CD27- CD4 T cells (THD cells) in NSCLC patients 
identify non-responders and hyperprogressors. The 
authors suggested that profiling of THD cells in pa-
tients prior to immunotherapies could help predict 
the patients having risk of HP. 
 Although the main research focused on adap-
tive immunity, the role of natural immunity in HP 
could not be underestimated. Accordingly, mono-
cytes and tumor-infiltrating dendritic cells exert 
immunosuppressive activity through Interleukin 
(IL)-10 release after anti-PD-1 treatment [67,68]. 
Moreover, some of the myeloid cells in the tumor 
microenvironment could lessen the effect of im-
mune-checkpoint blockade therapy through PD-L1 
expression or immunosuppression [69,70]. Recent-
ly, Lo Russo et al [30] reported the role of TAM pro-
gramming in mediating HP via Fc/FcR triggering 
macrophages by anti-PD-1 antibody. Interestingly, 
all NSCLC patients with HP displayed TM2-like 
CD163+ CD33+ PD-L1+ clustered epithelioid mac-
rophages. The authors suggested that ICIs promote 
reprogramming of clustered epithelial macrophag-
es (CD163+ CD33+ PD-L1+) into pro-tumorigenic 
phenotype via FcR-mediated signaling cascade, 
eventually inducing HPD. 
 Changes in mutational and transcriptional 
landscapes of pre- and post-therapy HPD tumors 
may explain the underlying mechanism of HP. In a 
comprehensive genomic study conducted by Xiong 
et al [71], it was described that two patients with 
HPD had increased deleterious somatic mutations 
in cancer genes such as TSC2 and VHL, with up-
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regulated oncogenic pathways such as IGF-1, ERK/
MAPK, PI3K/AKT, and TGF-β. More importantly, 
they outlined the significant changes in HPD tu-
mors. Firstly, HPD tumors were less immunogen-
ic, which may be caused by the downregulation 
of antigen-processing genes such HLA, B2M, and 
upregulation of other immune checkpoint genes 
including CTLA4, KDR, CD96, CD70, TNFRSF18, 
TNFRSF25, BTNL2, and TNFRS. Secondly, the ac-
tivity of T cells, dendritic cells, monocytes, natural 
killer cells, and CD4 helper T cells were weakened, 
whereas neutrophils were highly active in HPD tu-
mors. Thirdly, natural lymphoid cells (ILC3) were 
enriched in HPD tumors after anti-PD-1 treatment. 
It clearly seems that HPD tumors have unique gene 
expression signature along with changes in their 
microenvironment. Further genomics and tran-
scriptomics analysis should be done with more 
patietns with HPD to identify unique gene expres-
sion signature related to this phenomenon. 
Future prospects and concluding 
remarks
 Integration of immune checkpoint inhibitor-
based therapies into the oncology field has led to 
incredible improvements in the clinical outcomes 
of patients with multiple cancer types. However, 
accumulated studies revealed that a subset of pa-
tients has experienced paradoxically accelerated 
disease progression early after the initiation of im-
munotherapy. Until now, a small cohort of patients 
has been evaluated. Studies with higher numbers 
of patients and centers are urgently needed to reach 
a better understanding of HP. Moreover, there has 
been no universally accepted definition for HP and 
the methods (TGR, TGK) assessing clinical response 
have not been widely accepted by the clinical on-
cology community. Integrating pre-treatment 
tumor kinetics into clinical practice is critical to 
objectively discriminate HP from naturally ag-
gressive disease or pseudoprogression. To avoid 
an ineffective treatment, patients can be evaluated 
at earlier time periods (4-6 weeks). Future research 
should focus on achieving consensus for diagnostic 
criteria of HP and discovering putative biomarkers 
related to HP. In addition, molecular and immuno-
logical basis of HP has remained largely unknown. 
Genome profiling of patients with HPD might help 
elucidate biological mechanisms behind HP and 
design novel therapeutic interventions that would 
be beneficial for these patients. For this reason, it 
is highly recommended that the collection of sam-
ples including blood or tumor tissue upon disease 
progression should be considered in the clinical 
trials. Even though immune checkpoint inhibitors 
have been regarded as the primary reason for HP, 
no benchmarking studies have been conducted to 
determine whether ICIs induce HPD in patients. 
Accelerated tumor progression may occur in re-
sponse to intrinsic cancer biology or due to resist-
ance to immunotherapy. More efforts are needed 
for comprehensive analysis of various cells on the 
tumor microenvironment (T cells, Treg or Teff), 
tumor-associated macrophages (TAMs, M2 type), 
dendritic cells, myeloid-derived stem cells (MDSC), 
expression of immune checkpoints, cytokines, and 
inflammatory or inhibitory mediators with whole 
genome sequencing of tumor cells. Recently, sub-
sequent studies reported that chromosomal insta-
bility quantification by NGS from plasma/serum 
derived cell-free DNA (cfDNA) and the detection of 
genome instability number (GIN) by genome-wide 
sequencing of cfDNA could be used to discriminate 
clinical responses from progression, pseudopro-
gression, and HP [29,72]. Complementarily, these 
attempts contribute to explore the immune land-
scape in tumors and to discover biomarkers that 
could predict the HP in patients. 
 As immune checkpoint inhibitors have been 
more widely accepted by oncologists, a proper as-
sessment of tumor response remains challenging 
in clinical practice. Better survival outcomes in pa-
tients may lead physicians to fail to notice adverse 
events of immunotherapy. As mentioned above , an 
increasing body of evidence reveals that a small 
subset of patients is harmed by immune-blockade 
treatment. The distinct nature of HP has been sup-
ported by genomic and immunological analysis of 
HPD tumors. Moreover, patients with HPD have 
been presented with poor prognosis and increased 
deleterious mutations in cancer genes, along with 
alterations in the tumor microenvironment. Ac-
cordingly, these findings highlight the possibility 
of treatment-related adverse event. In conclusion, 
we suggest that HP should be explored as an ad-
verse event of immunotherapy. This issue warrants 
further investigation to answer the questions about 
this undesired phenomenon.
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